Verastem, Inc.
Verastem, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer on June 15, 2027. There are 6 upcoming events on record.
Cash runway is approximately 8.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 17 concluded trials, 53% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| June 15, 2027 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Trial Milestone | Phase 2 |
| June 15, 2027 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Trial Milestone | Phase 2 |
| June 15, 2027 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Trial Milestone | Phase 2 |
| August 1, 2027 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Trial Milestone | Phase 2 |
| October 15, 2028 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Trial Milestone | Phase 3 |
| December 15, 2028 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
Track VSTM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open VSTM in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.